InsidersTradesSigma
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
无可用的信号评分。
Explore the full record of transactions filed by Gerngross Tillman U., 董事. Insider active across 2 companies, notably Adagio Therapeutics, Inc.. In total, 3 disclosures have been published. Activity tracked since 16 June 2022. The latest transaction was disclosed on 14 June 2023 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 条申报中的 3 条
Tillman U. Gerngross is the Chief Executive Officer and Director at Adagio Therapeutics, Inc. and Alector, Inc. He leads the strategic and business operations of both companies, focusing on innovation in the biopharmaceutical sector. His leadership is essential in guiding the vision and growth of the companies.